Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials

References

• Coronavirus disease (COVID-19) [Internet]. Geneva: World Health Organization; [cited 2023 Feb 01]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
   Google Scholar
• Chifu I, Detomas M, Dischinger U, et al. Management of patients with glucocorticoid-related diseases and COVID-19. Front Endocrinol (Lausanne). 2021;12:705214.
   PubMed Web of Science ®Google Scholar
• Home [Internet]. America: Johns Hopkins Coronavirus Resource Center; [cited 2022 Sep 30]. Available from: https://coronavirus.jhu.edu/
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Triggle CR, Bansal D, Ding H, et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Front Immunol. 2021;12:631139.
   PubMed Web of Science ®Google Scholar
• Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol. 2020 Dec;42(6):669–680.
   PubMed Web of Science ®Google Scholar
• Cruz-Topete D, Cidlowski JA. One hormone two actions: anti- and pro-inflammatory effects of glucocorticoids. Neuroimmunomodulation. 2015;22:20–32.
   PubMed Web of Science ®Google Scholar
• Therapeutics and COVID-19: living guideline [Internet]. Geneva: World Health Organization; [2022 Jul 14; cited 2023 Jun 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582436/
   Google Scholar
• Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database Syst Rev. 2021;2021(8):CD014963.
   Google Scholar
• Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• 宁光,马志中,王卫庆, et al 糖皮质激素类药物临床应用指导原则 [Guidelines for clinical application of glucocorticoids]. 中华内分泌代谢杂志. 2012;28(2):171–202. Chinese
   Google Scholar
• Clinical management of COVID-19: living guideline [Internet]. Geneva: World Health Organization; [2022 Jun 23; cited 2023 Jan 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582435/
   Google Scholar
• 林苏杰,王芳,郝月琴,等. 《支气管哮喘防治指南(2020年版)》解读[Interpretation of the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition)]. 中国临床医生杂志. 2022;50(12):1406–1408. Chinese
   Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Recovery collaborative group; Horby P, LIM WS. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704 .
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772.
   PubMed Web of Science ®Google Scholar
• YU LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–855.
   PubMed Web of Science ®Google Scholar
• Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ. 2021;375:e068060.
   PubMedGoogle Scholar
• Clemency BM, Varughese R. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: a Randomized Clinical Trial. JAMA Intern Med. 2022;182(1):42–49.
   PubMed Web of Science ®Google Scholar
• Jamaati H, Hashemian SM, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947.
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• Ghanei M, Solaymani-Dodaran M, Qazvini A, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res. 2021;22(1):245.
   PubMed Web of Science ®Google Scholar
• Tang X, Feng YM, NI JX, et al. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: a Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021;100(2):116–126.
   PubMed Web of Science ®Google Scholar
• Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56(6):2002808.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, VAL FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, Placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–e381.
   PubMed Web of Science ®Google Scholar
• Corral-GUdino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia. Wien Klin Wochenschr. 2021;133(7–8):303–311.
   PubMed Web of Science ®Google Scholar
• Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–1306.
   PubMed Web of Science ®Google Scholar
• Angus D, Litton E, Lorenzi E, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA. 2020;324(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• MARIE M, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand. 2021;65(10):1421–1430.
   PubMed Web of Science ®Google Scholar
• Cheng W, LI Y, Cui L, et al. Efficacy and safety of corticosteroid treatment in patients with COVID-19: a systematic review and meta-analysis. Front Pharmacol. 2020;11:571156.
   PubMed Web of Science ®Google Scholar
• Pei L, Zhang S, Huang L, et al. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis. Pol Arch Intern Med. 2020;130(9):726–733.
   PubMedGoogle Scholar
• WHO RAPID EVIDENCE APPRAISAL FOR COVID-19 THERAPIES (REACT) working group; Sterne JAC, Murthy S. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
   PubMed Web of Science ®Google Scholar
• Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312–320.
   PubMed Web of Science ®Google Scholar
• Mohanty RR, Biswa Mohan P, Meher BR. Effectiveness of pulse dose methyl prednisolone in management of COVID 19: a systematic review and meta-analysis of observational studies. J Pharm Pharm Sci. 2022;25:110–123.
   PubMed Web of Science ®Google Scholar
• Noetzlin S, Breville G, Seebach JD, et al. Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. Swiss Med Wkly. 2022;152:w30088.
   PubMed Web of Science ®Google Scholar
• Bruscoli S, Puzzovio PG, Zaimi M, et al. Glucocorticoids and COVID-19. Pharmacol Res. 2022;185:106511.
   PubMed Web of Science ®Google Scholar